ULUR ULURU Inc (CE)

PART I – FINANCIAL INFORMATION

ITEM 1.

Financial Statements.

ULURU Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

		September 30, 2012				December 31, 2011
		(Unaudited)				(Audited)
ASSETS
Current Assets
Cash and cash equivalents		$	36,557			$	46,620
Accounts receivable, net			52,042				45,421
Other receivable, current portion			---				246,410
Notes receivable and accrued interest, current portion			255,333				---
Inventory			647,241				799,483
Prepaid expenses and deferred charges			202,290				211,522
Total Current Assets			1,193,463				1,349,456
Property, Equipment and Leasehold Improvements, net			911,117				1,072,460
Other Assets
Intangible assets, net			4,265,748				4,622,435
Notes receivable and accrued interest, net of current portion			1,276,665				---
Deferred financing costs, net			179,849				---
Deposits			18,069				18,069
Total Other Assets			5,740,331				4,640,504
TOTAL ASSETS		$	7,844,911			$	7,062,420
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable		$	1,993,557			$	1,640,211
Accrued liabilities			402,656				376,542
Accrued interest			36,080				13,053
Deferred revenue, current portion			45,227				24,061
Total Current Liabilities			2,477,520				2,053,867
Long Term Liabilities
Convertible notes payable, net of unamortized debt discount			2,000,866				234,882
Deferred revenue, net of current portion			846,953				672,282
Total Long Term Liabilities			2,847,819				907,164
TOTAL LIABILITIES			5,325,339				2,961,031
COMMITMENTS AND CONTINGENCIES			---				---
STOCKHOLDERS' EQUITY
Preferred stock - $0.001 par value; 20,000 shares authorized;
Preferred Stock Series A, 1,000 shares designated; 65 and 25 shares issued and outstanding, aggregate liquidation value of $689,555 and $254,387, at September 30, 2012 and December 31, 2011, respectively			---				---
Common Stock - $0.001 par value; 200,000,000 shares authorized;
8,653,289 and 7,269,063 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively			8,653				7,269
Additional paid-in capital			51,012,617				49,750,792
Promissory notes receivable and accrued interest for common stock issuance			(981,623	)			(725,045	)
Accumulated  (deficit)			(47,520,075	)			(44,931,627	)
TOTAL STOCKHOLDERS’ EQUITY			2,519,572				4,101,389
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$	7,844,911			$	7,062,420
The accompanying notes are an integral part of these condensed consolidated financial statements.

 

- 3 -

---

Table of Contents

ULURU Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2012				2011				2012				2011
REVENUES
License fees		$	11,400			$	6,184			$	29,163			$	18,349
Royalty income			16,633				18,861				49,918				51,528
Product sales, net			60,889				48,607				126,057				159,132
Total Revenues			88,922				73,652				205,138				229,009
COSTS AND EXPENSES
Cost of goods sold			113,415				11,065				135,745				35,545
Research and development			152,985				233,087				517,196				749,049
Selling, general and administrative			375,767				566,541				1,365,836				1,779,045
Amortization of intangible assets			119,763				206,454				356,687				612,632
Depreciation			75,219				75,359				225,691				227,665
Total Costs and Expenses			837,149				1,092,506				2,601,155				3,403,936
OPERATING (LOSS)			(748,227	)			(1,018,854	)			(2,396,017	)			(3,174,927	)
Other Income (Expense)
Interest and miscellaneous income			30,720				1,857				33,745				9,485
Interest expense			(134,218	)			(22,545	)			(191,008	)			(48,839	)
(LOSS) Before Income Taxes			(851,725	)			(1,039,542	)			(2,553,280	)			(3,214,281	)
Income taxes			---				---				---				---
NET (LOSS)		$	(851,725	)		$	(1,039,542	)		$	(2,553,280	)		$	(3,214,281	)
Less preferred stock dividends			(12,288	)			(462	)			(35,168	)			(462	)
NET (LOSS) Allocable to Common Stockholders		$	(864,013	)		$	(1,040,004	)		$	(2,588,448	)		$	(3,214,743	)
Basic and diluted net (loss) per common share		$	(0.10	)		$	(0.18	)		$	(0.32	)		$	(0.55	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING			8,267,755				5,928,084				8,106,117				5,850,900
The accompanying notes are an integral part of these consolidated financial statements.

 

- 4 -

---

Table of Contents

ULURU Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

		Nine Months Ended September 30,
		2012				2011
OPERATING ACTIVITIES :
Net loss		$	(2,553,280	)		$	(3,214,281	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of intangible assets			356,687				612,632
Depreciation			225,691				227,665
Share-based compensation for stock and options issued to employees			16,494				83,023
Share-based compensation for options issued to non-employees			21,745				45,884
Amortization of debt discount on convertible notes			53,029				2,831
Amortization of deferred financing costs			20,151				---
Cancellation of warrants issued for services			---				(38,994	)
Common stock issued for services			130,000				15,000
Common stock issued for interest due on convertible note			44,200				---
Change in operating assets and liabilities:
Accounts receivable			(6,621	)			22,060
Other receivable			26,410				(8,996	)
Inventory			152,243				(133,766	)
Prepaid expenses and deferred charges			9,232				(25,800	)
Notes receivable and accrued interest			(31,997	)			---
Accounts payable			353,346				657,920
Accrued liabilities			26,114				114,099
Accrued interest			23,027				6,373
Deferred revenue			195,837				81,651
Total			1,615,588				1,661,582
Net Cash Used in Operating Activities			(937,692	)			(1,552,699	)
INVESTING ACTIVITIES :
Purchase of property and equipment			(64,349	)			---
Proceeds from sale of intangible asset			220,000				250,000
Net Cash Provided by Investing Activities			155,651				250,000
FINANCING ACTIVITIES :
Proceeds from sale of common stock and warrants, net			---				411,990
Proceeds from sale of preferred stock, net			275,761				91,292
Proceeds from issuance of convertible notes and warrants, net			467,290				265,000
Offering cost adjustment – preferred stock sale in 2011			28,927				---
Cash paid in lieu of fractional shares			---				(35	)
Net Cash Provided by Financing Activities			771,978				768,247
Net Decrease in Cash			(10,063	)			(534,452	)
Cash,  beginning of period			46,620				641,441
Cash,  end of period		$	36,557			$	106,989
SUPPLEMENTAL CASH FLOW DISCLOSURE:
Cash paid for interest		$	3,747			$	2,386
Non-cash investing and financing activities:
Issuance of common stock for promissory note		$	245,818			$	323,182
Issuance of common stock for principle due on convertible note		$	39,133			$	---
The accompanying notes are an integral part of these condensed consolidated financial statements.

 

- 5 -

---

Table of Contents

ULURU Inc.

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1.

COMPANY OVERVIEW AND BASIS OF PRESENTATION

Company Overview

ULURU Inc. (hereinafter “we”, “our”, “us”, “ULURU”, or the “Company”) is a Nevada corporation.  We are a diversified specialty pharmaceutical company committed to developing and commercializing a broad range of innovative wound care and muco-adhesive film products based on our patented Nanoflex® and OraDisc TM drug delivery technologies, with the goal of improving outcomes for patients, health care professionals, and health care payers.

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and include the account of ULURU Inc., a Nevada corporation, and its wholly-owned subsidiary, Uluru Delaware Inc., a Delaware corporation.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete year-end financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of September 30, 2012, the results of its operations for the three and nine months ended September 30, 2012 and 2011, and cash flows for the nine months ended September 30, 2012 and 2011.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods.  Actual results may differ from those estimates and assumptions.  These differences are usually minor and are included in our consolidated financial statements as soon as they are known.  Our estimates, judgments, and assumptions are continually evaluated based on available information and experience.

All intercompany transactions and balances have been eliminated in consolidation.

Operating results for the three and nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012.

These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission on March 30, 2012, including the risk factors set forth therein.

 

- 6 -

---

Table of Contents

Liquidity and Going Concern

The report of our independent registered public accounting firm for the fiscal year ended December 31, 2011 contained an explanatory paragraph to reflect its significant doubt about our ability to continue as a going concern as a result of our history of losses and our liquidity position, as discussed herein and in this Form 10-Q.  Based on our existing liquidity, the expected level of operating expenses, projected sales of our existing products combined with other revenues, proceeds from the convertible debt transaction in June 2012, and proceeds from the divestiture of non-core assets, we believe that we will be able to meet our working capital and capital expenditure requirements through the second quarter of 2013.  However, we cannot be sure that our anticipated revenue growth will be realized or that we will generate significant positive cash flow from operations.  Moreover, we may not be able to raise sufficient additional capital on acceptable returns, or at all, to continue operations and may not be able to execute any strategic transactions.  Therefore, we are unable to assert that our financial position is sufficient to fund operations beyond the second quarter of 2013, and as a result, there is substantial doubt about our ability to continue as a going concern beyond the second quarter of 2013.

Explanatory Note Regarding Share Amounts:

All share amounts and per share prices in this Quarterly Report on Form 10-Q have been retroactively adjusted to reflect the effect of our reverse stock split, on a 15 for 1 basis, effective June 29, 2011, unless otherwise indicated.  The exercise price for all stock options and warrants and the conversion price for convertible debt in the accompanying condensed consolidated financial statements have been adjusted to reflect the reverse stock split by multiplying the original exercise or conversion price by fifteen.

NOTE 2.

SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three and nine months ended September 30, 2012 are consistent with those discussed in Note 2 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission on March 30, 2012.

 

- 7 -

---

Table of Contents

NOTE 3.

THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS

In September 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2011-08, “Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment” (“ASU 2011-08”). ASU 2011-08 updated guidance on the periodic testing of goodwill for impairment. This guidance will allow companies to assess qualitative factors to determine if it is more-likely-than-not that goodwill might be impaired and whether it is necessary to perform the two-step goodwill impairment test required under current accounting standards. This new guidance is effective for fiscal years beginning after December 15, 2011; however, early adoption is permitted in certain circumstances.  We adopted the provisions of ASU 2011-08 in the first quarter of 2012.  The adoption of this update does not materially impact our financial statements.

In June 2011, the FASB issued Accounting Standards Update No. 2011-05, “Comprehensive Income (Topic 220): Presentation of Comprehensive Income” (“ASU 2011-05”). ASU 2011-05 amended existing guidance by allowing only two options for presenting the components of net income and other comprehensive income: (1) in a single continuous financial statement of comprehensive income or (2) in two separate but consecutive financial statements, consisting of an income statement followed by a separate statement of other comprehensive income. Also, items that are reclassified from other comprehensive income to net income must be presented on the face of the financial statements. ASU No. 2011-05 requires retrospective application, and it is effective for fiscal years beginning after December 15, 2011.  We adopted the provisions of ASU 2011-05 in the first quarter of 2012.  The adoption of this update does not materially impact our financial statements.

In May 2011, the FASB issued Accounting Standards Update No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs” (“ASU 2011-04”). ASU 2011-04 generally provides a uniform framework for fair value measurements and related disclosures between U.S. generally accepted accounting principles and International Financial Reporting Standards. Additional disclosure requirements in the update include: (1) for Level 3 fair value measurements, quantitative information about unobservable inputs used, a description of the valuation processes used by the entity, and a qualitative discussion about the sensitivity of the measurements to changes in the unobservable inputs; (2) for an entity’s use of a nonfinancial asset that is different from the asset’s highest and best use, the reason for the difference; (3) for financial instruments not measured at fair value but for which disclosure of fair value is required, the fair value hierarchy level in which the fair value measurements were determined; and (4) the disclosure of all transfers between Level 1 and Level 2 of the fair value hierarchy. ASU 2011-04 will be effective for interim and annual periods beginning on or after December 15, 2011. We adopted the provisions of ASU 2011-04 in the first quarter of 2012.  The adoption of this update does not materially impact our financial statements.

 

- 8 -

---

Table of Contents

NOTE 4.

SEGMENT INFORMATION

We operate in one business segment: the research, development and commercialization of pharmaceutical products.  Our corporate headquarters in the United States collects product sales, licensing fees, royalties, and sponsored research revenues from our arrangements with external customers and licensees.  Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

Our revenues are currently derived primarily from one licensee for domestic activities, three licensees for international activities, and our sales force for the domestic sale of Altrazeal®.

Revenues per geographic area, along with relative percentages of total revenues, for the three and nine months ended September 30 are summarized as follows:

		Three Months Ended September 30,																Nine Months Ended September 30,
Revenues		2012				%				2011				%				2012				%				2011				%
Domestic		$	57,179				64	%		$	67,468				92	%		$	155,633				76	%		$	210,660				92	%
International			31,743				36	%			6,184				8	%			49,505				24	%			18,349				8	%
Total		$	88,922				100	%		$	73,652				100	%		$	205,138				100	%		$	229,009				100	%

A significant portion of our revenues are derived from a few major customers.  Customers with greater than 10% of total sales, along with their relative percentage of all sales, for the three and nine months ended September 30 are represented on the following table:

			Three Months Ended September 30,								Nine Months Ended September 30,
Customers	Product		2012				2011				2012				2011
Customer A	Aphthasol®			19	%			25	%			24	%			22	%
Customer B	Altrazeal®			29	%			---				15	%			---
Customer C	Altrazeal®			*				12	%			*				*
Total				48	%			37	%			39	%			22	%
* Sales from this customer were less than 10% of total sales for the period reported.

NOTE 5.

OTHER RECEIVABLE

On June 25, 2010, we entered into an acquisition and license agreement with Strakan International Limited and Zindaclin Limited, a subsidiary of Crawford Healthcare Limited, a pharmaceutical company based in England.  Under the terms of the agreement, Zindaclin Limited will pay up to $5.1 million for the exclusive product rights to Zindaclin®, a zinc clindamycin for the treatment of acne, which consideration will be shared equally by Strakan International Limited and us.  Guaranteed payments of $1,050,000 were scheduled to be received by us, of which $550,000 occurred in 2010, $250,000 occurred in 2011, and $250,000 was to occur in June 2012.  On March 22, 2012, we agreed to accept $220,000 for the early remittance of the final guaranteed payment, which was received prior to March 29, 2012.

 

- 9 -

---

Table of Contents

NOTE 6.

INVENTORY

As of September 30, 2012, our inventory was comprised of Altrazeal® finished goods, manufacturing costs incurred in the production of Altrazeal® and Aphthasol®, and raw materials.  Inventories are stated at the lower of cost (first in, first out method) or market.  We regularly review inventories on hand and write down the carrying value of our inventories for excess and potentially obsolete inventories based on historical usage and estimated future usage.  In assessing the ultimate realization of our inventories, we are required to make judgments as to future demand requirements.  As actual future demand or market conditions may vary from those projected by us, adjustment to inventories may be required.  For the three months ended September 30, 2012, we wrote off approximately $79,000 in out-of-date and obsolete finished goods.

The components of inventory, at the different stages of production, consisted of the following at September 30, 2012 and December 31, 2011:

Inventory		September 30, 2012				December 31, 2011
Finished goods		$	323,529			$	398,634
Work-in-progress			290,642				367,779
Raw materials			33,070				33,070
Total		$	647,241			$	799,483

NOTE 7.

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS

Property, equipment and leasehold improvements, net, consisted of the following at September 30, 2012 and December 31, 2011:

Property, equipment and leasehold improvements		September 30, 2012				December 31, 2011
Laboratory equipment		$	424,888			$	424,888
Manufacturing equipment			1,547,572				1,483,223
Computers, office equipment, and furniture			140,360				140,360
Computer software			4,108				4,108
Leasehold improvements			95,841				95,841
			2,212,769				2,148,420
Less: accumulated depreciation and amortization			( 1,301,652	)			(1,075,960	)
Property, equipment and leasehold improvements, net		$	911,117			$	1,072,460

Depreciation expense on property, equipment and leasehold improvements was $75,219 and $75,359 for the three months ended September 30, 2012 and 2011, respectively, and was $225,691 and $227,665 for the nine months ended September 30, 2012 and 2011, respectively.

 

- 10 -

---

Table of Contents

NOTE 8.

INTANGIBLE ASSETS

Intangible assets are comprised of patents acquired in October, 2005.  Intangible assets, net consisted of the following at September 30, 2012 and December 31, 2010:

Intangible assets		September 30, 2012				December 31, 2011
Patent - Amlexanox (Aphthasol®)		$	2,090,000			$	2,090,000
Patent - Amlexanox (OraDisc™ A)			6,873,080				6,873,080
Patent - OraDisc™			73,000				73,000
Patent - Hydrogel nanoparticle aggregate			589,858				589,858
			9,625,938				9,625,938
Less: accumulated amortization			( 5,360,190	)			(5,003,503	)
Intangible assets, net		$	4,265,748			$	4,622,435

Amortization expense for intangible assets was $119,763 and $206,454 for the three months ended September 30, 2012 and 2011, respectively, and was $356,687 and $612,632 for the nine months ended September 30, 2012 and 2011, respectively.

The future aggregate amortization expense for intangible assets, remaining as of September 30, 2012, is as follows:

Calendar Years		Future Amortization Expense
2012 (Three months)		$	119,763
2013			475,148
2014			475,148
2015			475,148
2016			476,450
2017 & Beyond			2,244,091
Total		$	4,265,748

NOTE 9.

INVESTMENTS IN UNCONSOLIDATED ENTITIES

On January 11, 2012, we executed a shareholders’ agreement for the establishment of Altrazeal Trading Ltd., a single purpose entity to be used for the exclusive marketing of Altrazeal® throughout the European Union, Australia, New Zealand, North Africa, and the Middle East.  As a result of this transaction, we received a non-dilutable 25% ownership interest in Altrazeal Trading Ltd.

We use the equity method of accounting for investments in other companies that are not controlled by us and in which our interest is generally between 20% and 50% of the voting shares or we have significant influence over the entity, or both.

As of September 30, 2012, Altrazeal Trading Ltd. had not begun operations and accordingly the net book value of the investee assets had not been determined and there were no equity method investee gains or losses for the three months and the nine months then ended.

 

- 11 -

---

Table of Contents

NOTE 10.

ACCRUED LIABILITIES

Accrued liabilities consisted of the following at September 30, 2012 and December 31, 2011:

Accrued Liabilities		September 30, 2012				December 31, 2011
Accrued taxes – payroll		$	106,299			$	106,299
Accrued compensation/benefits			252,924				184,080
Accrued insurance payable			41,379				78,246
Product rebates/returns			151				3,160
Other			1,903				4,757
Total accrued liabilities		$	402,656			$	376,542

NOTE 11.

CONVERTIBLE DEBT

On June 27, 2012, we entered into a Securities Purchase Agreement (the “Purchase Agreement”), related to our issue of a $2,210,000 Secured Convertible Note (the “June 2012 Note”), with Inter-Mountain Capital Corp., a Delaware corporation (“Inter-Mountain”).  The purchase price for the June 2012 Note was paid $500,000 at closing in cash and $1,500,000 in the form of six promissory notes in favor of the Company, each in the principal amount of $250,000 (the “Investor Notes”) and each of which becomes due as the outstanding balance under the June 2012 Note is reduced to certain levels.  The purchase price of the June 2012 Note reflected a $200,000 original issue discount and $10,000 in attorney’s fees. The Purchase Agreement also includes representations and warranties, restrictive covenants, and indemnification provisions standard for similar transactions.

The June 2012 Note bears interest at the rate of 8.0% per annum, with monthly installment payments of $83,333 commencing on the date that is the earlier of (i) thirty calendar days after the effective date of a registration statement registering the re-sale of the shares issuable upon conversion under the June 2012 Note and (ii) December 24, 2012, but in no event sooner than September 25, 2012.  At our option, subject to certain volume, price, and other conditions, the monthly installment payments on the June 2012 Note may be paid in whole, or in part, in cash or in our common stock.  If the monthly installment is paid in common stock, such shares being issued will be based on a price that is 80% of the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days.  The percentage declines to 70% if the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days is less than $0.05.

At the option of Inter-Mountain, the outstanding principal balance of the June 2012 Note may be converted into shares of our common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations.  The initial tranche is $710,000 and the six subsequent tranches are each $250,000, plus interest.  At our option, the outstanding principal balance of the June 2012 Note, or a portion thereof, may be prepaid in cash at 120% of the amount elected to be prepaid.  The June 2012 Note is secured by a Security Agreement pursuant to which we granted to Inter-Mountain a first-priority security interest in the assets held by the Company.

 

- 12 -

---

Table of Contents

Events of default under the June 2012 Note include failure to make required payments or to deliver shares upon conversion, the entry of a $100,000 judgment not stayed within 30 days, breach of representations or covenants under the transaction documents, various events associated with insolvency or failure to pay debts, delisting of our common stock, a restatement of financial statements, and a default under certain other agreements.  In the event of default, the interest rate under the June 2012 Note increases to 18% and the June 2012 Note becomes callable at a premium.  In addition, the holder has all remedies under law and equity, including foreclosing on our assets under the Security Agreement.

As part of the convertible debt financing, Inter-Mountain also received a total of seven warrants (the “Warrants”) to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the Warrants.  The Warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017.  The Warrant for the initial 785,714 shares of common stock vests immediately.  Each of the other Warrants vest upon the payment by the holder of each of the six Investor Notes.

As part of the convertible debt financing, we entered into a Registration Rights Agreement whereby we agreed to prepare and file with the SEC a registration statement for the number of shares referred to therein no later than July 27, 2012 and to cause such registration statement to be declared effective no later than ninety days after such filing with the SEC and to keep such registration statement effective for a period of no less than one hundred and eighty days.  The Registration Rights Agreement also grants Inter-Mountain piggy-back registration rights with respect to future offerings by the Company.  In accordance with our obligations under the Registration Rights Agreement, we filed with the SEC a registration statement that was declared effective on July 31, 2012.

On October 5, 2012, we and Inter-Mountain entered into a First Amendment to Buyer Trust Deed Note #1 (the “Trust Deed Note Amendment”) for the purpose of revising certain terms and conditions contained in the Buyer Trust Deed Note #1, to include an updated schedule for the timing of certain payment obligations by Inter-Mountain contained therein.

 

- 13 -

---

Table of Contents

On July 28, 2011, we completed a convertible debt financing for $125,000 with Mr. Kerry P. Gray, the Company’s Chairman, President, and Chief Executive Officer (the “July 2011 Note”).  The July 2011 Note bears interest at the rate of 10.0% per annum, with annual payments of interest commencing on July 1, 2012.  The full amount of principal and any unpaid interest will be due on July 28, 2014.  The outstanding principal balance of the July 2011 Note may be converted into shares of the Company’s common stock, at the option of the note holder and at any time, at a conversion price of $1.08 per share or 115,741 shares of common stock.  We may force conversion of the July 2011 Note if our common stock trades for a defined period of time at a price greater than $2.16.  The July 2011 Note is collateralized by the grant of a security interest in the inventory, accounts receivables and capital equipment held by the Company.  The securities issuable on conversion have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements.  As part of the convertible debt financing, Mr. Gray also received a warrant to purchase up to 34,722 shares of the Company’s common stock.  The warrant has an exercise price of $1.08 per share and is exercisable at any time until July 28, 2016.  On July 3, 2012, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2012 of $11,542 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date.  Moreover, the parties agreed that no Event of Default under the July 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2012.  Commencing on July 1, 2012, interest at the rate of 12.0% per annum will accrue on the deferred interest payment of $11,542 until the relevant payment date.

On June 13, 2011, we completed a $140,000 convertible debt financing with Mr. Gray (the “June 2011 Note”).  The June 2011 Note bears interest at the rate of 10% per annum, with annual payments of interest commencing on July 1, 2012.  The full amount of principal and any unpaid interest will be due on June 13, 2014.  The outstanding principal balance of the June 2011 Note may be converted into shares of the Company’s common stock, at the option of the note holder and at any time, at a conversion price of $1.20 per share or 116,667 shares of common stock.  We may force conversion of the convertible note if our common stock trades for a defined period of time at a price greater than $1.80.  The June 2011 Note is collateralized by the grant of a security interest in the inventory, accounts receivables, and capital equipment held by the Company.  The securities issuable on conversion have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements.  As part of the convertible debt financing, Mr. Gray also received a warrant to purchase up to 35,000 shares of the Company’s common stock.  The warrant has an exercise price of $1.20 per share and is exercisable at any time until June 13, 2016.  On July 3, 2012, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2012 of $14,653 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date.  Moreover, the parties agreed that no Event of Default under the June 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2012.  Commencing on July 1, 2012, interest at the rate of 12.0% per annum will accrue on the deferred interest payment of $14,653 until the relevant payment date.

We account for convertible debt using specific guidelines in accordance with U.S. GAAP.  We allocated the value of the proceeds received to the convertible instrument and to the warrant on a relative fair value basis.  We calculated the fair value of the warrant issued with the convertible instrument using the Black-Scholes valuation method, using the same assumptions used for valuing employee stock options, except the contractual life of the warrant was used. Using the effective interest method, the allocated fair value was recorded as a debt discount and is being amortized over the expected term of the convertible debt to interest expense.

On the date of issuance of the June 2011 Note, the July 2011 Note, and the June 2012 Note, no portion of the proceeds were attributable to a beneficial conversion feature since the conversion price of the June 2011 Note, the July 2011 Note, and the June 2012 Note exceeded the market price of the Company’s common stock.

Information relating to our convertible notes payable is as follows:

															As of September 30, 2012
Transaction		Initial  Principal Amount				Interest Rate			Maturity Date		Conversion Price (1)(2)				Principal Balance				Unamortized Debt Discount				Carrying Value
June 2011 Note		$	140,000				10.0	%	06/13/2014		$	1.20			$	140,000			$	6,909			$	133,091
July 2011 Note			125,000				10.0	%	07/28/2014		$	1.08				125,000				13,881				111,119
June 2012 Note			2,210,000				8.0	%	03/27/2015		$	0.35				2,170,867				414,211				1,756,656
Total		$	2,475,000												$	2,435,867			$	435,001			$	2,000,866

(1)	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of common stock at a fixed conversion price of $1.20 per share and $1.08 per shares, respectively.
(2)	The outstanding principal balance of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations.

The amount of interest cost recognized from the three convertible notes outstanding was $52,121 and $5,721 for three months ended September 30, 2012 and 2011, respectively and was $67,227 and $6,373 for the nine months ended September 30, 2012 and 2011, respectively.

 

- 14 -

---

Table of Contents

NOTE 12.

STOCKHOLDERS’ EQUITY

Common Stock

As of September 30, 2012, we had 8,653,289 shares of common stock issued and outstanding.  For the three months ended September 30, 2012, we issued 566,891 shares of common stock in payment of the convertible note installment of $83,333 due on September 25, 2012 to Inter-Mountain.

Preferred Stock

As of September 30, 2012, we had 65 shares of Series A preferred stock issued and outstanding.  For the three months ended September 30, 2012, we did not issue any shares of preferred stock.

Warrants

The following table summarizes the warrants outstanding and the number of shares of common stock subject to exercise as of September 30, 2012 and the changes therein during the nine months then ended:

		Number of Shares of Common Stock Subject to Exercise				Weighted – Average Exercise Price
Balance as of December 31, 2011			612,594			$	2.45
Warrants issued (1)			785,714				0.35
Warrants exercised			---				---
Warrants cancelled			---				---
Balance as of September 30, 2012			1,398,308			$	1.27

(1)

As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the warrants.  The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017.  The initial warrant for 785,714 shares of common stock vested on June 27, 2012 and only such shares of common stock have been included in this Table, based upon an exercise price of $0.35 per share of common stock.  Each of the other warrants vest upon the payment by Inter-Mountain of a related Investor Note.

Of the warrant shares subject to exercise as of September 30, 2012, expiration of the right to exercise is as follows:

Date of expiration		Number of Warrant Shares of Common Stock Subject to Expiration
July 23, 2014			69,050
May 15, 2015			357,155
June 13, 2016			35,000
July 16, 2016			116,667
July 28, 2016			34,722
June 27, 2017			785,714
Total			1,398,308

 

- 15 -

---

Table of Contents

NOTE 13.

EARNINGS PER SHARE

Basic and Diluted Net Loss Per Share

In accordance with FASB Accounting Standards Codification (“ASC”) Topic 260, Earnings per Share , basic earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period.  Diluted earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period, increased to include potential dilutive common shares.  The effect of outstanding stock options, restricted vesting common stock, convertible debt, convertible preferred stock, and warrants, when dilutive, is reflected in diluted earnings (loss) per common share by application of the treasury stock method.  We have excluded all outstanding stock options, restricted vesting common stock, convertible debt, convertible preferred stock, and warrants from the calculation of diluted net loss per common share because all such securities are antidilutive for all periods presented.

Shares used in calculating basic and diluted net loss per common share exclude these potential common shares as of September 30, 2012 and December 31, 2011:

		September 30, 2012				December 31, 2011
Warrants to purchase common stock (1)			1,398,308				612,594
Stock options to purchase common stock			158,409				287,745
Unvested restricted common stock			300				1,096
Common stock issuable upon the assumed conversion of our convertible note payable from June 2012 (2)			6,209,369				---
Common stock issuable upon the assumed conversion of our convertible notes payable from June 2011 and July 2011 (3)			378,790				232,408
Common stock issuable upon the assumed conversion of our Series A preferred stock (4)			985,078				357,143
Total			9,130,254				1,490,986

(1)	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the warrants.  The initial warrant for 785,714 shares of common stock vested on June 27, 2012 and only such shares of common stock have been included in this Table. Each of the other warrants vest upon the payment by Inter-Mountain of a related Investor Note.
(2)	The outstanding principal balance and the accrued and unpaid interest of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations.  For the purposes of this Table, we have assumed a conversion price of $0.35 per share and no ownership limitations.
(3)	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of common stock at a fixed conversion price of $1.20 per share and $1.08 per shares, respectively.  The accrued and unpaid interest for each convertible note payable may be converted, at the option of Mr. Gray, into shares of common stock at a conversion price based upon the average of the five trading days prior to the payment date, which for the purposes of this Table we have assumed to be September 30, 2012.
(4)	The outstanding Series A preferred stock and the accrued and unpaid dividends thereon are convertible into shares of the Company’s common stock at the Company’s option at any time after six-months from the date of issuance of the Series A preferred stock.  The conversion price for the holder is fixed at $0.70 per share with no adjustment mechanisms, resets, ratchets, or anti- covenants other than the customary adjustments for stock splits.  For the purposes of this Table, we have assumed a conversion price of $0.70 per share.

 

- 16 -

---

Table of Contents

NOTE 14.

SHARE BASED COMPENSATION

The Company’s share-based compensation plan, the 2006 Equity Incentive Plan (“Incentive Plan”), is administered by the compensation committee of the Board of Directors (“Board”), which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award.

We account for share-based compensation under FASB ASC Topic 718, Stock Compensation , which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values of the award on the grant date.  We use the Black-Scholes option-pricing model to estimate the fair value of share-based awards.

Our Board granted the incentive stock option awards as indicated below to executives or employees and nonstatutory stock option awards to directors or non-employees for the three and nine months ended September 30, 2012 and 2011:

		Three Months Ended September 30,								Nine Months Ended  September 30,
		2012				2011				2012				2011
Incentive Stock Options   (1)
Quantity			---				---				---				1,334
Weighted average fair value per share			---				---				---			$	1.15
Fair value			---				---				---			$	1,534
Nonstatutory Stock Options   (2)
Quantity			---				---				---				---
Weighted average fair value per share			---				---				---				---
Fair value			---				---				---				---

	(1)	The Company did not award any incentive stock options for the three months ended September 30, 2012 and 2011, respectively.
	(2)	The Company did not award any nonstatutory stock options for the three months ended September 30, 2012 and 2011, respectively.

Stock Options (Incentive and Nonstatutory)

The following table summarizes share-based compensation related to stock options for the three and nine months ended September 30, 2012 and 2011:

		Three Months Ended  September 30,								Nine Months Ended  September 30,
		2012				2011				2012				2011
Research and development		$	---			$	13,442			$	6,280			$	39,888
Selling, general and administrative			6,760				22,397				25,753				67,727
Total share-based compensation expense		$	6,760			$	35,839			$	32,033			$	107,615

At September 30, 2012, the balance of unearned share-based compensation to be expensed in future periods related to unvested stock option awards, as adjusted for expected forfeitures, is approximately $42,433.  The period over which the unearned share-based compensation is expected to be recognized is approximately two years.

The following table summarizes the stock options outstanding and the number of shares of common stock subject to exercise as of September 30, 2012 and the changes therein during the nine months then ended:

		Stock Options				Weighted Average Exercise Price per Share
Outstanding as of December 31, 2011			287,745			$	16.89
Granted			---				---
Forfeited/cancelled			(129,336	)			22.49
Exercised			---				---
Outstanding as of September 30, 2012			158,409			$	12.32

The following table presents the stock option grants outstanding and exercisable as of September 30, 2012:

Options Outstanding												Options Exercisable
Stock Options Outstanding				Weighted Average Exercise Price per Share				Weighted Average Remaining Contractual Life in Years				Stock Options Exercisable				Weighted Average Exercise Price per Share
	118,671			$	5.37				6.0				90,642			$	6.25
	19,335				23.80				4.9				19,335				23.80
	16,069				34.52				5.4				16,069				34.52
	4,334				69.22				4.6				4,334				69.22
	158,409			$	12.32				5.8				130,380			$	14.43

Restricted Stock Awards

Restricted stock awards, which typically vest over a period of two to five years, are issued to certain key employees and are subject to forfeiture until the end of an established restriction period.  We utilize the market price on the date of grant as the fair market value of restricted stock awards and expense the fair value on a straight-line basis over the vesting period.

The following table summarizes share-based compensation related to restricted stock awards for the three months and nine months ended September 30:

		Three Months Ended  September 30,								Nine Months Ended  September 30,
		2012				2011				2012				2011
Research and development		$	(391	)		$	3,742			$	2,814			$	12,462
Selling, general and administrative			1,143				2,652				3,392				8,830
Total share-based compensation expense		$	752			$	6,394			$	6,206			$	21,292

At September 30, 2012, the balance of unearned share-based compensation to be expensed in future periods related to restricted stock awards, as adjusted for expected forfeitures, is approximately $3,082.  The period over which the unearned share-based compensation related to restricted stock awards is expected to be recognized is approximately six months.

The following table summarizes the non-vested restricted stock awards outstanding and the number of shares of common stock subject to potential issue as of September 30, 2012 and the changes therein during the nine months then ended:

		Restricted stock				Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2011			1,096			$	41.47
Shares granted			---				---
Shares forfeited/cancelled			(97	)			34.59
Shares exercised/issued			(699	)			45.39
Outstanding as of September 30, 2012			300			$	34.59

Summary of Plans

2006 Equity Incentive Plan

In March 2006, our Board adopted and our stockholders approved our Incentive Plan, which initially provided for the issuance of up to 133,333 shares of our common stock pursuant to stock option and other equity awards.  At the annual meetings of the stockholders held on May 8, 2007, December 17, 2009, September 15, 2010, and June 14, 2012, our stockholders approved amendments to the Incentive Plan to increase the total number of shares of common stock issuable under the Incentive Plan pursuant to stock options and other equity awards by 266,667 shares, 200,000 shares, 200,000 shares, and 400,000 shares, respectively.

In December 2006, we began issuing stock options to employees, consultants, and directors.  The stock options issued generally vest over a period of one to four years and have a maximum contractual term of ten years.  In January 2007, we began issuing restricted stock awards to our employees.  Restricted stock awards generally vest over a period of six months to five years after the date of grant.  Prior to vesting, restricted stock awards do not have dividend equivalent rights, do not have voting rights, and the shares underlying the restricted stock awards are not considered issued and outstanding.  Shares of common stock are issued on the date the restricted stock awards vest.

As of September 30, 2012, we had granted options to purchase 408,667 shares of common stock since the inception of the Incentive Plan, of which 158,409 were outstanding at a weighted average exercise price of $12.32 per share and we had granted awards for 68,616 shares of restricted stock since the inception of the Incentive Plan, of which 300 were outstanding.  As of September 30, 2012, there were 972,145 shares that remained available for future grant under our Incentive Plan.

 

- 17 -

---

Table of Contents

NOTE 15.

FAIR VALUE MEASUREMENTS

In accordance with ASC Topic 820, Fair Value Measurements (“ASC Topic 820”), certain assets and liabilities of the Company are required to be recorded at fair value.  Fair value is determined based on the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants.  The guidance in ASC Topic 820 also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on our market assumptions.  Unobservable inputs require significant management judgment or estimation.  In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy.  In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement.  Such determination requires significant management judgment.

The three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies, is as follows:

Level 1

—

Valuations based on quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2

—

Valuations based on observable inputs other than quoted prices in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and other inputs that are observable or can be corroborated by observable market data.

Level 3

—

Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.

Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurements.  We review the fair value hierarchy classification on a quarterly basis.  Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

Our financial instruments, including cash, cash equivalents, accounts receivable, and accounts payable are carried at cost, which approximates their fair value because of the short-term maturity of these instruments.  We believe that the carrying value of our other receivable, notes receivable, and convertible notes payable balances approximates fair value based on a valuation methodology using the income approach and a discounted cash flow model.

 

- 18 -

---

Table of Contents

The following table summarizes the fair value of our financial instruments at September 30, 2012 and December 31, 2011.

 

Description		September 30, 2012				December 31, 2011
Assets:
Other receivable (1)		$	---			$	246,410
Notes receivable and accrued interest		$	1,531,998				---
Liabilities:
Convertible note – June 2011		$	133,091			$	129,781
Convertible note – July 2011		$	111,119			$	105,101
Convertible note – June 2012		$	1,756,656				---

(1)

The Company received remittance in March 2012.

NOTE 16.

INCOME TAXES

There was no current federal tax provision or benefit recorded for any period since inception, nor were there any recorded deferred income tax assets, as such amounts were completely offset by valuation allowances.

NOTE 17.

COMMITMENTS AND CONTINGENCIES

Operating Leases

On January 31, 2006, we entered into a lease agreement for office and laboratory space in Addison, Texas.  The lease commenced on April 1, 2006 and continues until April 1, 2013.  The lease required a minimum monthly lease obligation of $9,330, which is inclusive of monthly operating expenses, until April 1, 2011 and at such time increased to $9,776, which is inclusive of monthly operating expenses.  As of September 30, 2012 our current monthly lease obligation is $9,872, which is inclusive of monthly operating expenses.

On December 10, 2010, we entered into a lease agreement for certain office equipment.  The lease, which commenced on February 1, 2011 and continues until February 1, 2015, requires a minimum lease obligation of $744 per month.

The future minimum lease payments under the 2006 office lease and the 2010 equipment lease are as follows as of September 30, 2012:

Calendar Years		Future Lease Expense
2012 (Three months)		$	31,846
2013			38,542
2014			8,926
2015			744
2016			---
Total		$	80,058

Rent expense for our operating leases amounted to $32,971 and $33,083 for the three months ended September 30, 2012 and 2011, respectively, and $98,111 and $92,768 for the nine months ended September 30, 2012 and 2011, respectively.

 

- 19 -

---

Table of Contents

Indemnification

In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future, but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations.

In accordance with our restated articles of incorporation and our amended and restated bylaws, we have indemnification obligations to our officers and directors for certain events or occurrences, subject to certain limits, while they are serving at our request in their respective capacities. There have been no claims to date and we have a director and officer insurance policy that enables us to recover a portion of any amounts paid for future potential claims. We have also entered into contractual indemnification agreements with each of our officers and directors.

Employment Agreements

As of September 30, 2012, we were a party to employment agreements with our Vice President and Chief Financial Officer, Terrance K. Wallberg, and our Vice President – Polymer Drug Delivery, Daniel G. Moro.  The employment agreements with Messrs. Wallberg and Moro each have a term of one year and include an automatic one-year term renewal for each year thereafter.  Each employment agreement provides for a base salary, bonus, stock options, stock grants, and eligibility for our benefit programs.  Under certain circumstances, the employment agreements provide for certain severance benefits in the event of termination or a change in control.  The employment agreements also contain non-solicitation, confidentiality and non-competition covenants, and a requirement for the assignment of certain invention and intellectual property rights in favor of us.

Separation Agreements

As of September 30, 2012, we continue to be a party to a separation agreement with Renaat Van den Hooff, our former Chief Executive Officer, dated June 4, 2010.  Pursuant to the terms of the separation agreement we provide or have provided, as applicable, certain benefits to Mr. Van den Hooff, including: (i) payments of $12,500 per month for a period of eighteen (18) months; (ii) a non-statutory stock option to purchase up to 20,000 shares of our common stock, which option is immediately exercisable in full and at any time and from time to time through June 4, 2015 at a per share exercise price of $2.10 (the closing price of our common stock on June 4, 2010); (iii) full acceleration of all vesting schedules for all shares of restricted stock of the Company held by Mr. Van den Hooff; and (iv) for a period of eighteen (18) months following June 4, 2010 we were required to maintain and provide coverage under Mr. Van den Hooff’s existing health coverage plan.  The separation agreement contains a mutual release of claims and other standard provisions.

 

As of September 30, 2012, we continue to be a party to a separation agreement with Kerry P. Gray, dated March 9, 2009.  Mr. Gray currently serves as our Chairman of the Board, Chairman of the Board’s Executive Committee, Chief Executive Officer, and President.  Pursuant to the terms of the separation agreement, we provided certain benefits to Mr. Gray, including: (i) payments totaling $400,000 during the initial 12 month period following March 9, 2009; (ii) commencing March 1, 2010 and continuing for a period of forty-eight (48) months, the Company will continue to pay to Mr. Gray a payment of $12,500 per month; (iii) full acceleration of all vesting schedules for all outstanding Company stock options and shares of restricted stock of the Company held by Mr. Gray, with all such Company stock options remaining exercisable by Mr. Gray until March 1, 2012, provided that Mr. Gray forfeited 20,000 stock options previously held by him; and (iv) for a period of twenty-four (24) months following March 9, 2009 we were required to maintain and provide coverage under Mr. Gray’s existing health coverage plan.  The separation agreement contains a mutual release of claims, certain stock lock-up provisions, and other standard provisions.

Milestone Payments

Pursuant to the terms of an Asset Sale Agreement dated October 12, 2005, we acquired the assets of Access Pharmaceuticals, Inc. (“Access”).  Under that agreement, we are obligated to pay to Access for certain milestones based on our achievement of certain annual net sales, cumulative net sales, and/or our having reached certain defined technology milestones including licensing agreements and advancing products to clinical development.  As of September 30, 2012, the future milestone obligations that we are subject to paying Access, if the milestones related thereto are achieved, total $4,750,000.  Such milestones are based on total annual sales of $20 and $40 million dollars of certain products, annual sales of $20 million dollars of any one certain product, and cumulative sales of such products of $50 and $100 million dollars.

On March 7, 2008, we terminated an existing license agreement with ProStrakan Ltd. for Amlexanox-related products in the United Kingdom and Ireland.  As part of the termination, we agreed to pay ProStrakan Ltd. a royalty of 30% on any future payments received by us from a new licensee in the United Kingdom and Ireland territories, up to a maximum of $1,400,000.

NOTE 18.

SUBSEQUENT EVENTS

We have evaluated, for potential recognition and disclosure, subsequent events that have occurred after the balance sheet date but before the financial statements were available to be issued, which we consider to be the date of filing with the Securities and Exchange Commission.  No events have occurred that would require potential recognition or disclosure.

 

- 20 -

---

Table of Contents

ITEM 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis together with all financial and non-financial information appearing elsewhere in this report and with our consolidated financial statements and related notes included in our 2011 Annual Report on Form 10-K, referred to as our 2011 Form 10-K, which has been previously filed with the Securities and Exchange Commission on March 30, 2012, including the risk factors set forth therein.  In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involve risks and uncertainties, including the statement that our cash and cash equivalents are sufficient to fund our operations and capital expenditures through the second quarter of 2013.  Our actual results could differ materially from those anticipated by such forward-looking information due to competitive factors and other risks discussed in our 2011 Form 10-K under “Risks Associated with our Business”.

Business Overview

ULURU Inc. (hereinafter “we”, “our”, “us”, “ULURU”, or the “Company”) is a Nevada corporation.  We are a diversified specialty pharmaceutical company committed to developing and commercializing a broad range of innovative wound care and muco-adhesive film products based on our patented Nanoflex® and OraDisc TM drug delivery technologies, with the goal of improving outcomes for patients, health care professionals, and health care payers.

Our strategy is twofold:

§	Establish the foundation for a market leadership position in wound management by developing and commercializing a customer-focused portfolio of innovative wound care products based on the Nanoflex® technology to treat the various phases of wound healing; and
§	Develop our oral-transmucosal technology (OraDisc TM ) and generate revenues through multiple licensing agreements.

Utilizing our technologies, three of our products have been approved for marketing in various global markets.  In addition, numerous additional products are under development utilizing our patented Nanoflex® and OraDisc TM drug delivery technologies.

Altrazeal® Transforming Powder Dressing, based on our Nanoflex® technology, has the potential to change the way health care providers approach their treatment of wounds.  Launched in September 2008, the product is indicated for exuding wounds such as partial thickness burns, donor sites, abrasions, surgical, acute and chronic wounds.

Aphthasol®, our Amlexanox 5% paste product is the first drug approved by the FDA for the treatment of canker sores.

OraDisc™ A was initially developed as a drug delivery system to treat canker sores with the same active ingredient (amlexanox) that is used in Aphthasol® paste. We anticipate that higher amlexanox concentrations will be achieved at the disease site, increasing the effectiveness of the product.  OraDisc™ A was approved by the FDA in September 2004.

 

- 21 -

---

Table of Contents

Recent Developments

On September 20, 2012, we entered into a Binding Term Sheet (the “Term Sheet”) with an affiliate of Melmed Holding AG (“Melmed”) relating to an equity investment of $2,000,000 by Melmed for 5,000,000 shares of our common stock, par value $0.001 per share (the “Shares”) and warrants to purchase up to 3,000,000 shares of our common stock (the “Warrants”).  Under the Term Sheet, the purchase and sale of the Shares and Warrants will take place at four closings over the next twelve months, with $400,000 being funded upon signing of definitive documents.  The Warrants will have a fixed exercise price of $0.60 per share and may be exercised at any time and from time to time through and including the one-year anniversary thereof.  We have agreed to appoint up to two directors nominated by Melmed to serve on our Board of Directors.

Additionally, pursuant to the Term Sheet, Melmed will enter into a worldwide license and supply agreement with the Company related to certain dental applications of our OraDisc™ erodible film technology, to include benzocaine, amlexanox (exclusive of Europe), re-mineralization, fluoride, de-sensitizing, and long acting breath freshener.  We will receive a non-dilutable 25% ownership interest in a subsidiary that will be established to license the OraDisc™ rights and will also receive a 5% royalty on products sold worldwide.  The Company also agreed to expand the territory (currently European Union, Australia, New Zealand, North Africa, and the Middle East) in its existing license and supply agreement with Melmed Holding AG to include Asia (exclusive of China, Hong Kong, Macau, Taiwan, South Korea and Japan).

The Term Sheet, although binding, will be superseded by definitive agreements.

 

- 22 -

---

Table of Contents

RESULTS OF OPERATIONS

Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our quarterly and annual results of operations will be impacted for the foreseeable future by several factors, including the timing and amount of payments received pursuant to our current and future collaborations, and the progress and timing of expenditures related to our development and commercialization efforts. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results may not be a good indication of our future performance.

Comparison of the three months ended September 30, 2012 and 2011

Total Revenues

Revenues were approximately $89,000 for the three months ended September 30, 2012, as compared to revenues of approximately $74,000 for the three months ended September 30, 2011, and were comprised of, in approximate numbers, licensing fees of $11,000 from Altrazeal® and OraDisc™ licensing agreements, royalties of $17,000 from the sale of Aphthasol® by our domestic distributor, and Altrazeal® product sales of $61,000.

The third quarter 2012 revenues represent an overall increase of approximately $15,000 versus the comparative third quarter 2011 revenues.  The increase in revenues is primarily attributable to an increase of approximately $12,000 in Altrazeal® product sales and an increase of approximately of $5,000 in Altrazeal® licensing fees.  These revenue increases were partially offset by a decrease of approximately $2,000 in Aphthasol® royalties from our domestic distributor.

Costs and Expenses

Cost of Goods Sold

Cost of goods sold for the three months ended September 30, 2012 was approximately $113,000 and was comprised of $34,000 from the sale of our Altrazeal® products and $79,000 from the write-off of out-of-date and obsolete finished goods.  Cost of goods sold for the three months ended September 30, 2011 was approximately $11,000 and was comprised entirely of costs associated with the sale of our Altrazeal® products.

 

- 23 -

---

Table of Contents

Research and Development

Research and development expenses totaled approximately $153,000 for the three months ended September 30, 2012, including approximately nil in share-based compensation, compared to approximately $233,000 for the three months ended September 30, 2011, which included approximately $17,000 in share-based compensation.  The decrease of approximately $80,000 in research and development expenses was primarily due, in approximate numbers, to a $20,000 decrease in costs for regulatory consulting and a $60,000 decrease in scientific compensation costs related to share-based compensation and a lower head-count.

The direct research and development expenses for the three months ended September 30, 2012 and 2011 were as follows:

		Three Months Ended September 30,
Technology		2012				2011
Wound care & nanoparticle		$	30,000			$	31,000
OraDisc™			4,000				3,000
Aphthasol® & other technologies			1,000				---
Total		$	35,000			$	34,000

Selling, General and Administrative

Selling, general and administrative expenses totaled approximately $376,000 for the three months ended September 30, 2012, including $8,000 in share-based compensation, compared to approximately $567,000 for the three months ended September 30, 2011, which included $25,000 in share-based compensation.

The decrease of approximately $191,000 in selling, general and administrative expenses was primarily due, in approximate numbers, to a $51,000 decrease in costs for compensation as a result of the termination of payments associated with a separation agreement with our former President and reduced share-based compensation, a $47,000 decrease in consulting costs for investor relations costs, a $29,000 decrease in sales and marketing costs due to a revised sales and marketing plan, a $16,000 decrease in insurance costs, a $14,000 decrease in legal expenses, a $12,000 decrease due to reduced corporate travel, a $8,000 decrease in fees associated with listing exchange fees, a $7,000 decrease for reduced consulting services, a $4,000 decrease in legal costs relating to our patents, and a $3,000 decrease in costs for director fees.

Amortization of Intangible Assets

Amortization of intangible assets expense totaled approximately $120,000 for the three months ended September 30, 2012 as compared to approximately $206,000 for the three months ended September 30, 2011.  The expense for each period consists primarily of amortization associated with our acquired patents.  The decrease of approximately $86,000 is attributable to the expiration of the amortization of the Aphthasol® patent in November 2011.  There were no additional purchases of patents during the three months ended September 30, 2012 and 2011, respectively.

 

- 24 -

---

Table of Contents

Depreciation

Depreciation expense totaled approximately $75,000 for the three months ended September 30, 2012 as compared to approximately $75,000 for the three months ended September 30, 2011.

Interest and Miscellaneous Income

Interest and miscellaneous income totaled approximately $31,000 for the three months ended September 30, 2012 as compared to approximately $2,000 for the three months ended September 30, 2011.  The increase of approximately $29,000 is attributable to an increase in interest income resulting from interest recognized from the outstanding notes receivable with Inter-Mountain Capital Corp.

Interest Expense

Interest expense totaled approximately $134,000 for the three months ended September 30, 2012 as compared to approximately $22,000 for the three months ended September 30, 2011.  Interest expense is comprised of financing costs for our insurance policies, interest costs related to regulatory fees, and interest costs and amortization of debt discount related to our convertible debt.  The increase of approximately $112,000 is primarily attributable to costs associated with our convertible debt and interest costs relating to regulatory fees.

 

- 25 -

---

Table of Contents

Comparison of the nine months ended September 30, 2012 and 2011

Total Revenues

Revenues were approximately $205,000 for the nine months ended September 30, 2012, as compared to revenues of approximately $229,000 for the nine months ended September 30, 2011, and were comprised of, in approximate numbers, licensing fees of $29,000 from Altrazeal® and OraDisc™ licensing agreements, $50,000 of royalties from the sale of Aphthasol® by our domestic distributor, and Altrazeal® product sales of $126,000.

The nine months ended September 30, 2012 revenues represent an overall decrease of approximately $24,000 versus the comparative nine months ended September 30, 2011 revenues.  The decrease in revenues is primarily attributable to a decrease of approximately $33,000 in Altrazeal® product sales and a decrease of approximately $2,000 in royalties from the sale of Aphthasol® by our domestic distributor.  The revenue decrease was partially offset by an increase of approximately $11,000 in Altrazeal® licensing fees.

Costs and Expenses

Cost of Goods Sold

Cost of goods sold for the nine months ended September 30, 2012 was approximately $136,000 and was comprised of $48,000 of costs from the sale of our Altrazeal® products and $88,000 from the write-off of out-of-date and obsolete finished goods.  Cost of goods sold for the nine months ended September 30, 2011 was approximately $36,000 and was comprised entirely of costs associated with the sale of our Altrazeal® products.

Research and Development

Research and development expenses totaled approximately $517,000 for the nine months ended September 30, 2012, including approximately $9,000 in share-based compensation, compared to approximately $749,000 for the nine months ended September 30, 2011, which included approximately $52,000 in share-based compensation.  The decrease of approximately $232,000 in research and development expenses was primarily due, in approximate numbers, to an $88,000 decrease in scientific compensation costs related to share-based compensation and a lower head count, an $80,000 decrease in direct research costs, a $50,000 decrease in costs for regulatory consulting, and a $14,000 decrease in maintenance costs.

The direct research and development expenses for the nine months ended September 30, 2012 and 2011 were as follows:

		Nine Months Ended September 30,
Technology		2012				2011
Wound care & nanoparticle		$	46,000			$	127,000
OraDisc™			12,000				9,000
Aphthasol® & other technologies			3,000				5,000
Total		$	61,000			$	141,000

 

- 26 -

---

Table of Contents

Selling, General and Administrative

Selling, general and administrative expenses totaled approximately $1,365,000 for the nine months ended September 30, 2012, including approximately $29,000 in share-based compensation, compared to approximately $1,779,000 for the nine months ended September 30, 2011, which included approximately $77,000 in share-based compensation.

The decrease of approximately $414,000 in selling, general and administrative expenses was primarily due, in approximate numbers, to a $147,000 decrease in compensation costs as a result of the termination of payments associated with a separation agreement with our former President and reduced share-based compensation, a $164,000 decrease in sales and marketing costs due to a revised sales and marketing plan, a $66,000 decrease in legal costs relating to our patents, a decrease of $19,000 in fees associated with listing exchange fees, a $19,000 decrease in consulting costs, a $16,000 decrease in insurance costs, a $15,000 decrease due to reduced corporate travel costs, a $15,000 decrease in costs associated with our annual meeting of shareholders held in June 2012, a $12,000 decrease in costs for director fees, an $11,000 decrease in legal expenses, a $9,000 decrease in operating costs, and a $6,000 decrease in bad debt expense.  These expense decreases were partially offset, in approximate numbers, by a $25,000 increase in consulting costs for investor relations, the cost of $28,000 associated with the early remittance of the receivable from our divestiture of the Zindaclin® technology in June 2010, the cost of $24,000 for the litigation settlement with R.C.C. Ventures, LLC, and a $8,000 increase in accounting fees for the annual audit.

Amortization of Intangible Assets

Amortization of intangible assets expense totaled approximately $357,000 for the nine months ended September 30, 2012 as compared to approximately $613,000 for the nine months ended September 30, 2011.  The expense for each period consists primarily of amortization associated with our acquired patents.  The decrease of approximately $256,000 is attributable to the expiration of the amortization of the Aphthasol® patent in November 2011.  There were no additional purchases of patents during the nine months ended September 30, 2012 and 2011, respectively.

Depreciation

Depreciation expense totaled approximately $226,000 for the nine months ended September 30, 2012 as compared to approximately $228,000 for the nine months ended September 30, 2011.  The decrease of approximately $2,000 is attributable to certain equipment being fully depreciated.

Interest and Miscellaneous Income

Interest and miscellaneous income totaled approximately $34,000 for the nine months ended September 30, 2012 as compared to approximately $9,000 for the nine months ended September 30, 2011.  The increase of approximately $25,000 is primarily attributable to an increase in interest income resulting from interest recognized from the outstanding notes receivable with Inter-Mountain.

Interest Expense

Interest expense totaled approximately $191,000 for the nine months ended September 30, 2012 as compared to approximately $49,000 for the nine months ended September 30, 2011.  Interest expense is comprised of financing costs for our insurance policies, interest costs related to regulatory fees, and interest costs and amortization of debt discount related to our convertible debt.  The increase of approximately $142,000 is primarily attributable to costs associated with our convertible debt and interest costs relating to regulatory fees.

 

- 27 -

---

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

We have funded our operations primarily through the public and private sales of convertible notes and common stock.  Product sales, royalty payments, contract research, licensing fees and milestone payments from our corporate alliances have provided, and are expected in the future to provide, funding for operations. Our principal source of liquidity is cash and cash equivalents.  As of September 30, 2012, our cash and cash equivalents were $36,557 which is a decrease of $10,063 as compared to our cash and cash equivalents at December 31, 2011 of $46,620.  Our working capital (defined as current assets less current liabilities) was $(1,284,057) at September 30, 2012 as compared to our working capital at December 31, 2011 of $(704,411).

Consolidated Cash Flow Data

		Nine Months Ended September 30,
Net Cash Provided by (Used in)		2012				2011
Operating activities		$	(937,692	)		$	(1,552,699	)
Investing activities			155,651				250,000
Financing activities			771,978				768,247
Net Decrease in cash and cash equivalents		$	(10,063	)		$	(534,452	)

Operating Activities

For the nine months ended September 30, 2012, net cash used in operating activities was approximately $938,000.  The principal components of net cash used in operating activities for the nine months ended September 30, 2012 were our net operating loss of approximately $2,553,000 and an increase in notes receivable of approximately $32,000 due to the accrual of interest income.  Our net loss for the nine months ended September 30, 2012 included substantial non-cash charges of approximately $868,000 in the form of share-based compensation, amortization of patents, depreciation, amortization of debt discount, amortization of deferred financings costs, and common stock issued for services.  The aforementioned net cash used for the nine months ended September 30, 2012 was partially offset by an increase in deferred revenue of approximately $196,000 due primarily to the receipt of licensing milestone payments, an increase in accounts payable of approximately $353,000 due to timing of vendor payments, an increase in accrued liabilities of approximately $26,000, an increase in accrued interest of approximately $23,000 relating to our convertible debt, a decrease in inventory of approximately $152,000 due primarily to the write-off of out-of-date and obsolete inventory and product sales, a decrease in receivables of approximately $20,000, and a decrease in prepaid expenses of approximately $9,000 due primarily to expense amortization.

For the nine months ended September 30, 2011, net cash used in operating activities was approximately $1,553,000.  The principal components of net cash used for the nine months ended September 30, 2011 were our net loss of approximately $3,214,000, an increase of approximately $134,000 in inventory related to the manufacture of Aphthasol®, and an increase in prepaid expenses of approximately $26,000.  Our net loss for the nine months ended September 30, 2011 included substantial non-cash charges of approximately $948,000 in the form of share-based compensation, amortization of patents, and depreciation.  The aforementioned net cash used for the nine months ended September 30, 2011 was partially offset by an increase in accounts payable of approximately $658,000 due to timing of vendor payments, an increase in accrued expense of approximately $114,000, an increase in deferred revenue of approximately $82,000, an increase in accrued interest of approximately $6,000 relating to our convertible debt, and a decrease in receivables of approximately $13,000 due to collection activities.

 

- 28 -

---

Table of Contents

Investing Activities

Net cash provided by investing activities for the nine months ended September 30, 2012 was approximately $156,000 and is comprised of the fourth and final payment to us of $220,000 from the divestiture of our Zindaclin® intangible asset and a purchase of manufacturing equipment for approximately $64,000.

Net cash provided by investing activities for the nine months ended September 30, 2011 was $250,000 and relates to the third payment to us, received in June 2011, from the divestiture of our Zindaclin® intangible asset.

Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2012 was approximately $772,000 and was comprised of, in approximate numbers, $276,000 from the net proceeds of our sale of preferred stock in January 2012, $467,000 of net proceeds from the convertible debt transaction in June 2012, and $29,000 from a decrease in the estimate of offering costs associated with the sale of preferred stock in 2011.

Net cash provided by financing activities for the nine months ended September 30, 2011 was approximately $768,000 and was comprised of, in approximate numbers, $91,000 from the sale of preferred stock in September 2011, $412,000 from the sale of common stock in January 2011, and $265,000 from the two convertible debt offerings, which occurred in June and July 2011.  The net cash provided by the aforementioned financing activities was partially offset by our payment of cash in lieu of fractional shares of common stock associated with the Company’s reverse stock split on June 29, 2011 in the amount of $35.

 
 

Liquidity

In July 2009, we restructured our operations in efforts to reduce operating expenses, optimize operations, and to conserve the necessary cash to further our business plan.  These conservation efforts were in place during 2010 and 2011 and will continue to be in effect as part of our strategic plan for 2012.  Currently, a core management group is being supplemented by a small selection of external consultants to support our primary business activities.  Selling efforts for Altrazeal® are continuing with our own sales force and a network of independent sales representatives throughout the country.

We continue to seek strategic relationships whereby we can more effectively maximize the revenue potential of Altrazeal®, future product candidates, as well as continuing, with the assistance of an investment bank, to explore future fundraising and through the sale of non-core assets.

 

- 29 -

---

Table of Contents

As of October 31, 2012, we had cash and cash equivalents of approximately $200,000.  We expect to use our cash, cash equivalents, and investments on working capital, general corporate purposes, products, product rights, technologies, property and equipment, the payment of contractual obligations, and regulatory or sales milestones that may become due.  Our long-term liquidity will depend to a great extent on our ability to fully commercialize our Altrazeal® and OraDisc™ technologies; therefore we are continuing to search both domestically and internationally for opportunities that will enable us to continue our business.  At this time, we cannot accurately predict the effect of certain developments on the rate of sales growth, if any, during 2012 and beyond, such as the degree of market acceptance, patent protection and exclusivity of our products, the impact of competition, the effectiveness of our sales and marketing efforts, and the outcome of our current efforts to develop, receive approval for, and successfully launch our near-term product candidates.

Based on our existing liquidity, the expected level of operating expenses, projected sales of our existing products combined with other revenues, proceeds from the convertible debt transaction in June 2012, and proceeds from the divestiture of non-core assets, we believe that we will be able to meet our working capital and capital expenditure requirements through the second quarter of 2013.  We do not expect any material changes in our capital expenditure spending during 2012.  However, we cannot be sure that our anticipated revenues will be realized or that we will generate significant positive cash flow from operations.  We are unable to assert that our financial position is sufficient to fund operations beyond the second quarter of 2013, and as a result, there is substantial doubt about our ability to continue as a going concern.

As we continue to expend funds to advance our business plan, there can be no assurance that changes in our research and development plans, capital expenditures and/or acquisitions of products or businesses, or other events affecting our operations will not result in the earlier depletion of our funds.  In appropriate situations, we may seek financial assistance from other sources, including contribution by others to joint ventures and other collaborative or licensing arrangements for the development, testing, manufacturing and marketing of products under development.  Additionally, we may receive additional proceeds from the repayment of the Investor Notes received as part of our convertible debt financing, and we may explore alternative financing sources for our business activities, including the possibility of loans from banks and public and/or private offerings of debt and equity securities.  On September 20, 2012, we entered the Term Sheet with Melmed relating to a pending equity investment of $2,000,000 by Melmed for 5,000,000 shares of our common stock and warrants to purchase up to 3,000,000 shares of our common stock. Under the Term Sheet, the purchase and sale of such shares and warrants will take place at four closings over the next twelve months, with $400,000 being funded upon signing of definitive documents.  Other than the Term Sheet and the Investor Notes from Inter-Mountain, we have no agreements with respect to our potential receipt of capital.  We cannot be certain that necessary funding will be available on terms acceptable to us, or at all.

Our future capital requirements and adequacy of available funds will depend on many factors including:

§	Our ability to successfully commercialize our wound management and burn care products and the market acceptance of these products;
§	Our ability to establish and maintain collaborative arrangements with corporate partners for the research, development and commercialization of certain product opportunities;
§	Continued scientific progress in our development programs;
§	The costs involved in filing, prosecuting and enforcing patent claims;
§	Competing technological developments;
§	The cost of manufacturing and production scale-up; and
§	Successful regulatory filings.

 

- 30 -

---

Table of Contents

Contractual Obligations

The following table summarizes our outstanding contractual cash obligations as of September 30, 2012, which consists of a lease agreement for office and laboratory space in Addison, Texas which commenced on April 1, 2006, a lease agreement for office equipment, separation agreements with a former chief executive officer and our current chief executive officer, Kerry P. Gray, two convertible note agreements with Kerry P. Gray, and one convertible note agreement with Inter-Mountain.

		Payments Due By Period
Contractual Obligations		Total				Less Than 1 Year				2-3 Years				4-5 Years				After 5 Years
Operating leases		$	80,058			$	68,156			$	11,902			$	---			$	---
Separation agreements			265,841				203,341				62,500				---				---
Convertible notes			2,736,611				1,052,691				1,683,920				---				---
Total contractual cash obligations		$	3,082,510			$	1,324,188			$	1,758,322			$	---			$	---

Off-Balance Sheet Arrangements

As of September 30, 2012, we did not have any off balance sheet arrangements.

Impact of Inflation

We have experienced only moderate price increases over the last three fiscal years under our agreements with third-party manufacturers as a result of raw material and labor price increases.  However, there can be no assurance that possible future inflation would not impact our operations.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Management’s Discussion and Analysis of Financial Condition and Results of Operations addresses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. The preparation of our financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate these estimates and judgments. We base our estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.  Our critical accounting policies are summarized in our Annual Report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission on March 30, 2012.  We had no significant changes in our critical accounting policies since our last annual report.

 

- 31 -

---

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q (including documents incorporated by reference) and other written and oral statements the Company makes from time to time contain certain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the fact they use words such as “should”, “expect”, “anticipate”, “estimate”, “target”, “may”, “project”, “guidance”, “intend”, “plan”, “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts.  Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These statements include, among other things, statements regarding the Company’s expected cash and cash equivalents and working capital being sufficient to fund our operations and capital expenditure requirements through the second quarter of 2013, and other statements, including the Company’s goals, plans and projections regarding its financial position, results of operations, cash flows, market position, product development, product approvals, sales efforts, expenses, performance or results of current and anticipated products and the outcome of contingencies such as legal proceedings, and financial results, which are based on current expectations that involve inherent risks and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years.  The Company has included important factors in the cautionary statements included in its 2011 Annual Report on Form 10-K, particularly under “Risk Associated with our Business” that we believe could cause actual results to differ materially from any forward-looking statement.

 

Although we believe we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved and readers are cautioned not to place undue reliance on such statements, which speak only as of the date made.  The Company undertakes no obligation to release publicly any revisions to forward-looking statements as a result of new information, future events or otherwise.

 

- 32 -

---

Table of Contents

ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk .

Concentrations of Credit Risk

Concentration of credit risk with respect to financial instruments, consisting primarily of cash and cash equivalents, potentially expose us to concentrations of credit risk due to the use of a limited number of banking institutions and due to maintaining cash balances in banks, which, at times, may exceed the limits of amounts insured by the Federal Deposit Insurance Corporation.  Currently, we utilize Bank of America and Bank of America Investment Services, Inc. as our banking institutions.  At September 30, 2012 and December 31, 2011 our cash and cash equivalents totaled $36,557 and $46,620, respectively.  However, because deposits are maintained at these two financial institutions, we do not believe that there is a significant risk of loss of uninsured amounts.  We also invest cash in excess of immediate requirements in money market accounts, certificates of deposit, corporate commercial paper with high quality ratings, and U.S. government securities.  These investments are not held for trading or other speculative purposes.  We are exposed to credit risk in the event of default by these high quality banking institutions.

Concentration of credit risk with respect to trade accounts receivable is limited to certain customers with balances that exceed 5% of total consolidated trade accounts receivable at September 30, 2012 and at December 31, 2011.  As of September 30, 2012, two customers exceeded the 5% threshold, each customer with 42% and 31% of total consolidated trade accounts receivable, respectively.  Four customers exceeded the 5% threshold at December 31, 2011, each customer with 36%, 24%, 14%, and 6% of total consolidated trade accounts receivable, respectively.  To reduce risk, we routinely assess the financial strength of our most significant customers and monitor the amounts owed to us, taking appropriate action when necessary.  As a result, we believe that accounts receivable credit risk exposure is limited.  We maintain an allowance for doubtful accounts, but historically have not experienced any significant losses related to an individual customer or group of customers.

ITEM 4.

Controls and Proce dures.

Evaluation of Disclosure Controls and Procedures.

Our chief executive officer and our chief financial officer, after evaluating the effectiveness of our “disclosure controls and procedures” (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this quarterly report, concluded that our disclosure controls and procedures were (1) designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our chief executive officer and chief financial officer by others within the Company, particularly during the period in which this report was being prepared, and (2) effective, in that they provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

Changes in internal controls.

There were no changes in our internal controls over financial reporting during the quarter ended September 30, 2012 that have materially affected, or are reasonably likely to material affect, our internal controls over financial reporting.

 

- 33 -

---

Table of Contents

PART II - OTHER INFORMATION

ITEM 1.

Legal Proceedings.

On November 6, 2012, a Complaint was filed against the Company in the United States District Court, Central District of California, by Discus Dental, LLC (“Discus”) and Philips Oral Healthcare Inc. (“Philips”); together with Discus, the (“Plaintiffs”).  Discus is a subsidiary of Philips, and at least one of the Plaintiffs is party to a license agreement under which the Company granted it right to, and contractually required that it use commercially reasonable efforts to, market and sell Aphthasol®, an oral health care product.  The Company believes that the Plaintiffs have not fulfilled their obligations under the license agreement, including retaining an adequate selling organization and otherwise using reasonable efforts to market and sell Aphthasol®.  In response to Company demands, the Plaintiffs filed the Complaint to seek declaratory judgments that Discus did not breach the license agreement, that claims arising from events prior to November 2008 have been released, that the Company is not entitled to damages referenced in demand letters sent by the Company, that certain liability limitation provisions apply and that Philips has no obligation under the license agreement because it is not a party to the agreement.  The Plaintiffs seek no monetary award other than reasonable costs and expenses.

The Company believes that the Plaintiffs have not complied with certain provisions of the licensing agreement for Aphthasol® and that the Company has suffered economic damages.  The Company intends to vigorously defend its position and is evaluating its defenses and counterclaims.

ITEM 1A.

Risk Factors.

This item is not applicable to smaller reporting companies; provided, however, there have been no material changes in the risk factors disclosed in Part I, Item 1A, of our 2011 Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 30, 2012, except as follows:

We granted a security interest in all of our assets in connection with our recent convertible debt financing in June 2012

In connection with our issuance of a $2,210,000 promissory note in favor of Inter-Mountain in June 2012, we entered into a Security Agreement to secure obligations of the Company under the June 2012 Note in favor of Inter-Mountain.  If we default under the June 2012 Note, the holders will be entitled to foreclose on all of our assets pursuant to the Security Agreement.

Our financing with Inter-Mountain will be diluted to existing shareholders, and may be increasingly dilutive under certain circumstances.

Pursuant to the terms of June 12 Note, at our option, subject to certain volume, price, and other conditions, the monthly installment payments on the June 2012 Note may be paid in whole, or in part, in cash or in our common stock.  If the monthly installment is paid in common stock, such shares being issued will be based on a price that is 80% of the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days.  The percentage declines to 70% if the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days is less than $0.05.  Any election we make to pay monthly installments will be dilutive existing shareholders.

In addition, at the option of Inter-Mountain, the outstanding principal balance of the June 2012 Note may be converted into shares of our common stock at a conversion price of $0.35 per share.  If we sell, or are deemed to have sold, common stock below $0.35 per share in the future, the conversion price will be reduced to the price at which we sell, or are deemed to have sold common stock.  The initial amount that may be converted is $710,000, and as Inter-Mountain pays down certain promissory notes in our favor, up to six subsequent tranches of $250,000, plus interest, may be eligible for conversion.  Inter-Mountain also received a total of seven warrants to purchase, if they all vest, an aggregate of 3,142,857 shares of common stock, which number of shares could increase based upon the terms and conditions of the Warrants.  The Warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017.  The Warrant for the initial 785,714 shares of common stock vested immediately.  Each of the other Warrants vest upon the payment by the holder of each of the six notes issued by Inter-Mountain in our favor.  Any issuance upon conversion of the June 2012 Note, or the exercise of related warrants, will be diluted to existing shareholders.

 

- 34 -

---

Table of Contents

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

On June 27, 2012, we issued the June 2012 Note to Inter-Mountain for a purchase price paid $500,000 at closing in cash and $1,500,000 in the form of six promissory notes in favor of the Company.  Under the June 2012 Note, we are required to make monthly payments of $83,333, which may be made, at our discretion, in cash or, subject to certain volume, price, and other conditions, in common stock.  In addition, at the option of Inter-Mountain, the outstanding principle balance of the June 2012 Note may be converted into shares of our common stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations.  During the quarter ended September 30, 2012, we issued an aggregate of 566,891 shares of common stock to Inter-Mountain as part of the payment of monthly installments, or conversions, under the June 2012 Note.

Such shares were issued in reliance upon the exemptions for sales of securities not involving a public offering, as set forth in Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”) and/or Regulation D promulgated thereunder, based upon the following: (a) the investor confirmed that it was an “accredited investor,” as defined in Rule 501 of Regulation D promulgated under the Securities Act and  had such background education and experience in financial and business matters as to be able to evaluate the merits and risks of an investment in the securities; (b) there was no public offering or general solicitation with respect to the offering; (c) the investor was provided with certain disclosure materials and all other information requested with respect to the Company; (d) the investor acknowledged that the securities being purchased were “restricted securities” for purposes of the Securities Act and agreed to transfer the underlying securities only in a transaction registered under the Securities Act or exempt from registration under the Securities Act; (e) a Form D was filed with the Commission; and (f) the shares are subject to restrictions on transfer.

ITEM 3.

Defaults Upon Senior Securities.

None.

ITEM 4.

Mine Safety Disclosures

Not applicable.

ITEM 5.

Other Information.

None.

 

- 35 -

---

Table of Contents

ITEM 6.

Exhibits .

 

Exhibit Number		Description
10.41	*	Binding Term Sheet dated September 20, 2012 by and between ULURU Inc. and Regenertec Invest GmbH
31.1	*	Certification of Principal Executive Officer of ULURU Inc. Pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Amended
31.2	*	Certification of Principal Accounting Officer of ULURU Inc. Pursuant to Rule 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Amended
32.1	**	Certification of Chief Executive Officer of ULURU Inc. Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	**	Certification of Chief Financial Officer of ULURU Inc. Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	***	XBRL Instance Document
101.SCH	***	XBRL Taxonomy Extension Schema Document
101.CAL	***	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	***	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	***	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	***	XBRL Taxonomy Extension Presentation Linkbase Document
---------------------------------------------------
	*	Filed herewith.
	**	This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933 or the Securities and Exchange Act of 1934.
	***	Pursuant to Rule 406T of Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		ULURU Inc.
Date:  November 14, 2012		By:	/s/ Kerry P. Gray
			Kerry P. Gray
			Chief Executive Officer and President
			(Principal Executive Officer)
Date:  November 14, 2012		By:	/s/ Terrance K. Wallberg
			Terrance K. Wallberg
			Chief Financial Officer and Vice President
			(Principal Financial and Accounting Officer)

 

 

 

- 36 -

---